Ildong Begins R&D Transformation With 'Quick Win, Fast Fail' Strategy
Role For Internal/External Collaborations
South Korea’s Ildong Pharmaceutical has begun a major transformation from an OTC-focused firm to an innovative R&D-based operation that aims to compete with global big pharma rivals, helped by both internal and external alliances, its R&D head says in an interview with Scrip.
